The Milky Way may not collide with neighboring galaxy Andromeda after all: 'From near-certainty to a coin flip'
When you buy through links on our articles, Future and its syndication partners may earn a commission.
A titanic cosmic collision between the Milky Way and its closest large galactic neighbor, Andromeda, may not be as sure a thing as scientists thought. Previously, it had been proposed that there was a good chance that Andromeda and our galactic home, which are moving together, would meet in around 5 billion years and merge to form a daughter galaxy dubbed "Milkomeda."
New research has revealed that there is a much smaller chance that these two spiral galaxies will slam into each other and merge over the next 10 billion years than was believed. In fact, it's about 50/50.
"Our main finding is that the merger between the Milky Way and Andromeda, which had been predicted to occur in around 4.5 billion years, is actually much less certain. We found only about a 50% chance that this merger will happen during the next 10 billion years," team leader and University of Helsinki researcher Til Sawala told Space.com. "In short, the probability went from near-certainty to a coin flip.
"I was prepared to find something different, but yes, the fact that there is only around a 50/50 chance of a merger was very surprising."
Sawala and colleagues reached this conclusion by simulating the next 10 billion years of the Milky Way's journey through the universe.This new simulation was based on updated astronomical data from the Hubble Space Telescope and from the European Space Agency (ESA) star tracking mission Gaia. The team also factored in new estimates of the masses of smaller dwarf galaxies around the Milky Way, which, via their gravitational influence, impact the cosmic passage of the Milky Way.
"The main difference between our research and previous studies is that we benefited from newer and more precise data, and that we considered a more complete system, including the effect of the Large Magellanic Cloud, the Milky Way's largest satellite galaxy," Sawala said.
The team was able to present different scenarios of what could become of the Milky Way and Andromeda galaxies as they gradually move together."A head-on collision is very unlikely, we found a less than 2% chance for that. In most of the cases that lead to a merger, the two galaxies will indeed fly past each other at first, which will lead to a loss of orbital energy, and subsequently to a merger," Sawala said. "How close they come on their first passage is very uncertain, however, and if they don't come very close, meaning if their distance is more than around 500,000 light-years, they might not merge at all."
The researchers found that if the orbits of the Milky Way and Andromeda come close enough for the two galaxies to gravitationally influence each other, then a merger is an eventuality.
"But it's almost equally likely that they stay well separated, in which case they won't merge, and also continue to evolve mostly in isolation,"
The team found that while the odds of a merger with Andromeda drop when the Large Magellanic Cloud's influence is considered, with this adjustment, the Milky Way becomes more likely to cannibalize this satellite dwarf galaxy.According to this research, our galaxy is almost certain to merge with the Large Magellanic Cloud over the next 2 billion years.
Related Stories:
— Why do dwarf galaxies line up? 'Zippers' and 'twisters' in the early universe may solve a galactic mystery
— Scientists calculate when the universe will end — it's sooner than expected
— Amateur astrophotographer captures a stunning galaxy 24 million light-years from Earth (photo)
"Of course, now we really want to find out whether the Milky Way and Andromeda will collide or not," Sawala said. "That will not only need more observational data, but also more complete modelling of their interaction, as well as of the effect of the environment in which they evolve. "Luckily, there will be more observational data coming very soon, next year, from the Gaia Space Telescope, and perhaps also from the Hubble Space Telescope."
The team's research was published on Monday (June 2) in the journal Nature Astronomy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
a day ago
- Bloomberg
Regime Change Could Make Iran Even More Confrontational
Welcome back to The Forecast from Bloomberg Weekend, where we help you think about the future — from next week to next decade. We've tweaked our format just a tad! Let us know what you think by emailing: weekend@
Yahoo
2 days ago
- Yahoo
Weight loss in your 40s and 50s can help slash your chronic disease risk, researchers say
Working to lose weight in your 40s and 50s may help to reduce your risk of developing a chronic disease, a new study reveals. Researchers based in the U.K. and Finland say they found health benefits in people who lost an average of 6.5 percent of their body weight in early middle age and maintained that weight loss throughout a period of 12 to 35 years. Those benefits especially include a lessened risk for cardiovascular disease and diabetes as well as an overall lower risk of death from chronic disease. 'The benefits of lifestyle-based weight management are widely discussed even though studies have found it surprisingly difficult to demonstrate health benefits beyond the prevention of diabetes,' University of Helsinki professor Dr. Timo Strandberg said in a statement. Strandberg was the lead author of the study which was published recently in the journal JAMA Network Open, the open-access journal of the American Medical Association. To reach these conclusions, the study tracked and analyzed the health of 23,000 white Europeans who were between the ages of 30 and 50 years old using data from three studies, conducted from 1985 to 1988, from 1964 to 1973, and between 2000 and 2013. They sorted the participants into four groups: people with persistent healthy weight, people who were overweight but became a healthy weight, people who were healthy and became overweight, and people who were overweight the entire time. 'Measurement of weight and height was conducted at a time when surgical and pharmacological weight-loss interventions were nearly nonexistent,' the authors noted. The cause of weight loss was not assessed, but given the age of the participants and lack of diagnosed disease, it was more likely intentional than caused by severe chronic conditions or frailty.' In one study, a reduction in body mass from overweight to normal weight over six years in mid-life was tied to a lower risk of developing chronic diseases. There was also a 48 percent lower risk for chronic illness compared to those who remained overweight, which largely held even after excluding participants who developed diabetes during follow-up. Another study showed a 57 percent risk for chronic illness. A third study, with the longest follow-up period, showed that weight loss in mid-life was associated with a 19 percent reduction in overall mortality. 'I'm certain that overall prevention of overweight and obesity starting in early life is absolutely the best thing to do,' Stranberg told The Independent. 'Our study indirectly proves this by showing that persistent healthy weight over the life-course is best.' He said that he hopes the findings will inspire people to see that lifestyle changes can lead to a longer life. 'This is particularly important today as more people are overweight than when the collection of our research data began 35 years ago,' he said in the statement.
Yahoo
2 days ago
- Yahoo
Just 1 dose of magic mushroom compound eases depression for at least 5 years in most patients, small study suggests
When you buy through links on our articles, Future and its syndication partners may earn a commission. DENVER—Psilocybin, the main psychoactive ingredient in magic mushrooms, can alleviate depression for at least five years after a single dose, a new study finds. The research, presented June 18 at the Psychedelic Science 2025 conference in Denver, focused on patients with major depressive disorder (MDD), which is often called clinical depression. The serious mood disorder causes a persistent feeling of sadness and a loss of interest or pleasure in activities that were once enjoyable. The most common treatments for MDD include talk therapy and medications such as selective serotonin reuptake inhibitors, and both can take a long time to show any benefits. When early studies hinted at psilocybin's potential as an antidepressant, a team of researchers undertook the first-ever randomized clinical trial to explore the use of the psychedelic for treating severe depression. The trial included 24 patients, half of whom received psilocybin at the very start of the trial and half of whom received the same dose eight weeks later—the "waitlist" group. Each patient also received 11 hours of psychotherapy. Even in that short time frame, "there was a significant reduction in depression in the immediate-treatment group compared to those on the waitlist," study co-author Alan Davis, director of the Center for Psychedelic Drug Research and Education at The Ohio State University, told Live Science. Once all of the patients had completed the four-week study, the psilocybin appeared to be four times more effective than traditional antidepressant medications, based on previous research data. One month after the treatment, 17 patients had relieved symptoms, including 14 who were in full remission from depression. Patients also responded much faster to psilocybin than is typical for conventional antidepressants. But do these benefits of psilocybin last? Related: Magic mushrooms temporarily 'dissolve' brain network responsible for sense of self Very few long-term studies of psilocybin for depression have been conducted to date, said Dr. Charles Raison, a professor of human ecology and psychiatry at the University of Wisconsin-Madison who was not involved in the research. "They are very difficult to do because people drop out," Raison told Live Science in an email. "But also because they go on all sorts of other treatments that obfuscate the degree to which any longer lasting benefits result from the psychedelic or because the participant got therapy or restarted an antidepressant." To investigate whether the benefits for psilocybin lasted and if the patients had experienced any side effects, the researchers contacted the original trial participants several years later to request their enrollment in a follow-up study. Twenty-one patients enrolled, and their clinicians rated any changes in the participants' levels of depression from before the original treatment to the present day. The patients also filled out a series of self-reported, online questionnaires and met up with clinicians to document their ability to engage in everyday tasks, their levels of anxiety and their general mental health. The researchers assumed that the three patients that didn't sign up for the follow up, and the three that didn't complete the questionnaires had not remained in remission. Even so, the researchers found that 67% of the participants who had suffered from depression half a decade earlier remained in remission after a single psychedelic therapy session. These patients also reported less anxiety and less difficulty functioning on a daily basis. In general, the two-thirds of the patients who responded well reported lasting positive changes in their mindsets, emotional health and relationships. "I'm excited by these deeper aspects of their lives that really speaks to the importance of these interventions beyond just reduction of depression," Davis said. RELATED STORIES —Psychedelics rapidly change the brain. Here's how. —Australia clears legal use of MDMA and psilocybin to treat PTSD and depression —'Magic mushroom' treatment for depression inches closer to approval Most of the patients shared that, following the original treatment, they'd engaged in self-reflection and therapy to help understand themselves and navigate life's challenges. Davis hypothesizes that the psychedelic experience catalyzes a deeper therapy process and would like to conduct future studies comparing the relative influences of psilocybin and psychotherapy in alleviating depression. "The biggest caveat of this study is the small sample size, and the fact that the original trial showed larger antidepressant effects than subsequent larger multi-site studies seem to be showing," Raison said. In a multi-site clinical trial with 233 participants, 37% of the 79 who received a single 25 mg dose of psilocybin, coupled with psychotherapy, went into remission from major depression. While these trials report less widespread antidepressant effects, they support the idea that psilocybin can effectively treat depression, Davis said, and he is keen to see how the findings of multi-site trials hold up five years post-treatment.
